Vertixanthone
Vertixanthone is an antifungal agent, with MIC values of 3.125 μg/mL against Candida albicans CMCC 98001 and 12.5 μg/mL against Aspergillus niger R330. Vertixanthone can be used for the research of candida albicans infection, aspergillus niger infection.
For research use only. We do not sell to patients.
- CAS No.: 120461-93-0
- Formula: C15H10O5
- Molecular Weight:270.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Vertixanthone (0-50.0 μg/mL; 24-48 h) potently inhibits Candida albicans CMCC 98001 with an MIC of 3.125 μg/mL and inhibits Aspergillus niger R330 with an MIC of 12.5 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 120461-93-0
-
Molecular Weight 270.24
-
Formula C15H10O5
-
SMILES
O=C(OC)C=1C=CC=C2OC=3C=CC=C(O)C3C(=O)C21
-
Structure Classification
-
Initial Source
Paraconionthyrium sp. YM 311593
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)